You are here

Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG060836-01
Agency Tracking Number: R41AG060836
Amount: $249,507.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PAS17-065
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-30
Award End Date (Contract End Date): 2019-08-31
Small Business Information
Lubbock, TX 79424-3125
United States
DUNS: 079262912
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (806) 743-2385
Business Contact
Phone: (806) 441-8460
Research Institution
LUBBOCK, TX 79424-3125
United States

 Domestic Nonprofit Research Organization

Project SummaryThe objective of our proposed research is to develop a water soluble molecule that can reduce
the levels of amyloid betaAand Drpand prevent abnormal interactions between Aand Drpin
Alzheimers diseaseADaffected neuronsOur previous AD studies foundincreased production and
accumulation of Aand increased expression of Drpandan abnormal interaction between Aand
Drpin AD neurons that was associated with synaptic dysfunctionmitochondrialmtdamageand
dysfunction of neurons affected by ADA therapeutic strategy for AD may involve treating AD affected
neurons with molecules designed to reduce Aand Drplevels and to inhibit the interaction of Aand
DrpVery few molecules have been developed to prevent ADbut those that are the most promising are
insoluble in waterrendering them problematic treatments due to water insolubilityThereforein this
project we are proposing to develop a water soluble molecule capable of reducing Aand Drplevels in
AD neurons and of inhibiting the interaction between Aand DrpTo achieve this objectivewe have
developed technology and have designed and producedmolecular crystal structuresincluding DDQdiethyldihydroxyphenethylaminoquinolinyl methylphosphonateWe selected DDQ for the
proposed research to reduce Aand Drpinteraction at specific interacting sites in the ADrpcomplex
and exhibits the best docking capabilities of allstructures and received the best docking scoreDDQ
also readily bound to Drpindependently and while Drpinteracted with AWe synthesized DDQ by
following retro synthesis analysis and analyzed its structure spectrallyWe tested DDQ in AD affected
neuronsusing different methodologiesand measured the production of Aand expression of Drpafter
DDQ docked with DrpOur preliminary studieswhich includedhuman cells incubated with Aand
treated with DDQ andfurther transfected human cells with mutant APP cDNA and treated with DDQand characterized Aand DDQ treated cells and mutant APP transfected and DDQ treated cells for
mRNAusing qRT PCRADrpinteractionsusing Co IPwestern blot analysisimmunocytochemistryand ultrastructural changesusing electron microscopyThese studies revealed
that DDQ reduced Aand Drplevels as well as ADrpinteractions and protect AD affected cells from
synaptic and mt toxicitiesThe current application seeksto determine the blood brain barrier crossing
properties and pharmacokinetics of DDQ in wildtype miceto measure cognitive behavior in the DDQtreated anduntreated APP transgenic miceTglineandto determine the protective effects of
DDQ in terms of reducing the interaction of Aand DrpThe outcome of our application will determine
the drug delivery characteristics of DDQ and whether it is capable of targeting and binding to AD neurons
and protecting them from Aand Drpinduced toxicitiesThe proposed research will also provide new
information about DDQ for future AD clinical trials Project NarrativeThe elevated levels of Aand increased expressions of mitochondrial fission protein Drpand
abnormal interactions between Aand Drphave been found to induce synaptic dysfunction and
mitochondrial oxidative damagecausing neuronal damage in Alzheimers diseaseADneuronsThe
primary objective of the proposed research is to develop the water soluble drug molecule DDQwhichbased on our preliminary studiesappears to be capable of reducing the Aand Drplevelsand of
inhibiting interactions between Aand DrpIn our proposed experimentswe will determine whether
DDQ enhances neuronal function and survival in AD affected neuronsand through pharmacokinetic and
and animal studies of ADwe will characterize drug properties of DDQincluding whether DDQ can cross
the blood brain barrierwhich will indicate whether DDQ is a promising drug molecule that may slow AD

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government